Why cerebellar glioblastoma is rare and how that indicates adjunctive use of the FDA-approved anti-emetic aprepitant might retard cerebral glioblastoma growth: a new hypothesis to an old question.
Kast
Richard E
RE
D000932:Antiemetics / Q000627:therapeutic use*; D000077608:Aprepitant; D002526:Cerebellar Diseases / Q000188:drug therapy* / Q000453:epidemiology* / Q000473:pathology; D002528:Cerebellar Neoplasms / Q000188:drug therapy* / Q000453:epidemiology* / Q000473:pathology; D005909:Glioblastoma / Q000188:drug therapy* / Q000453:epidemiology* / Q000473:pathology; D006801:Humans; D009025:Morpholines / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D000932:Antiemetics; D009025:Morpholines; D000077608:Aprepitant